FutureCeuticals, Inc. is excited to announce that its joint health solution, FruiteX-B®, is now available for commercial use in the European Union (EU) through the company’s EU distributor, vaneeghen.
In 2019, FutureCeuticals, Inc. submitted an application to the European Commission to consider calcium fructoborate, commercially known as FruiteX-B®, for novel food status. In May 2021, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) finished its evaluation of the supporting data and released its opinion that FruiteX-B is safe as a novel food in accordance with EU regulations.
“We are thrilled that FruiteX-B achieved novel food status and is now available to companies in the EU looking for safe and effective joint health ingredients,” says Randy Wexler, VP General Counsel, and the head of Research and Development at FutureCeuticals. “We are looking forward to expanding the FruiteX-B brand into the EU through our partnership with vaneeghen.”
“vaneeghen is proud to bring this innovative brand to the EU market,” states Erik Bakkers, Innovation and Marketing Director at vaneeghen. “We officially launched FruiteX-B in May 2022 and are excited to connect with potential partners looking to create their next successful joint health product.”
FruiteX-B is a patented, vegan, mineral complex called calcium fructoborate that is identical to the same compound found in nature in certain fruits, vegetables, nuts, and legumes.
FruiteX-B has a long history of safety and clinical efficacy in supporting improved joint comfort and mobility with over two decades of research and commercial market success in the United States.
Visit vaneeghen.com to learn more.
vaneeghen is a family-owned company with over 360 years of experience in the distribution of food ingredients. Over the years, we have evolved into a leading international distributor of branded ingredients, vitamins, botanicals, minerals and other nutrients for infant nutrition and supplement markets.